Compare Amgen, Inc. (AMGN) vs Marathon Digital Holdings Inc (MARA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Marathon Digital Holdings Inc — how do they compare? Amgen, Inc. trades at $363.55 (market cap $196.12B), while Marathon Digital Holdings Inc trades at $12.46 (market cap $4.80B). The key difference: Amgen, Inc. is far larger — about 40.9× Marathon Digital Holdings Inc's market cap, and Amgen, Inc. pays a 2.77% dividend while Marathon Digital Holdings Inc pays none. Which is the better fit depends on your goals.
| AMGN | MARA | |
|---|---|---|
Market Cap | $196.12B | $4.80B |
Sector | Health | Technology |
52-Week High | $388.16 | $22.84 |
52-Week Low | $271.18 | $6.73 |
Enterprise Value | $241.41B | $6.75B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
MARA Holdings trades at $12.60, down 4.69% on the day, amid mixed signals. The stock shows a bullish technical trend with strong support at $12, while fundamentals reveal deep losses with a net income margin of -234.83% in 2026. Recent news highlights a strategic pivot to AI infrastructure, including a Texas land acquisition adding 2 GW power capacity, driving investor optimism despite earnings misses.
Outlook hinges on successful execution of AI data center expansion, offering growth potential but carrying high execution risk. Analysts maintain a $17.88 price target (50% buy rating), yet persistent cash burn and competitive pressures pose significant downside risks. Stock appears speculative, balancing transformative opportunities against substantial financial challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Marathon Digital Holdings Inc
Marathon Digital Holdings, Inc. is one of the largest publicly traded Bitcoin mining companies in North America. The company focuses on building and operating large-scale, cost-efficient Bitcoin mining facilities. Marathon's strategy centers on increasing its mining hash rate and using sustainable energy sources to expand its Bitcoin production. The company's performance is closely tied to the price of Bitcoin and the overall health of the digital asset mining industry.
Read more on MARA →
